期刊文献+

替格瑞洛与氯吡格雷治疗在冠心病患者中的应用及效果对比分析 被引量:2

Analysis of Comparison and Application Effect of Ticagrelor and Clopidogrel in Treatment of Patients with Coronary Heart Disease
下载PDF
导出
摘要 目的对比分析替格瑞洛与氯吡格雷治疗在冠心病患者中的应用及效果。方法将2014年1月—2017年1月该院收治的冠心病患者105例为研究对象,数字法分为两组,氯吡格雷组55例,替格瑞洛组50例,比较两组患者的治疗情况。结果替格瑞洛组患者的MACE总发生率(6.0%)低于氯吡格雷组(20.0%),两组之间比较差异有统计学意义(P<0.05)。结论在冠心病治疗中,替格瑞洛组MACE发生率、出血率和不良反应发生率低,应用效果显著。 Objective To compare and analyze the application effect of ticagrelor and clopidogrel in treatment of patients with coronary heart disease.Methods 105 cases of patients with coronary heart disease admitted and treated in our hospital from January 2014 to January 2017 were selected and randomly divided into two groups,including 55 cases in the ticagrelor group and 50 cases in the clopidogrel group,and the treatment situation was compared between the two groups.Results The total incidence rate of MACE in the ticagrelor group was lower than that in the clopidogrel group(6.0%vs 20.0%),and the difference was statistically significant(P<0.05).Conclusion The incidence rate of MACE,hemorrhage rate and incidence rate of adverse reactions of ticagrelor in treatment of patients with coronary heart disease are lower,and the application effect is obvious.
作者 张婷 ZHANG Ting(Department of Cardiovascular Medicine,Hefei Second People’s Hospital,Hefei,Anhui Province,230000 China)
出处 《系统医学》 2017年第22期49-50,53,共3页 Systems Medicine
关键词 替格瑞洛 氯吡格雷 冠心病 应用及效果 Ticagrelor Clopidogrel Coronary heart disease Application and its effect
  • 相关文献

参考文献10

二级参考文献60

  • 1刘大一,王智昊.替格瑞洛在老年ST段抬高型心肌梗死患者急诊冠状动脉介入治疗中的应用[J].中国老年学杂志,2014,34(10):2638-2641. 被引量:21
  • 2Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J, 2012 Aug 24. [ Epub ahead of print].
  • 3杨晓伟,张君毅,易甫,等.替格瑞洛对急性冠状动脉综合征择期介入治疗患者近中期疗效观察[J].中华临床医师杂志(电子版),2013,7(19):8696-8700.
  • 4Price MJ, Berger PB, Teirstein PS, et al. Standard-仍 high-dose clopidogrel based on platelet function testing afterpercutaneous coronary intervention: the gravitas randomizedtrial[J]. JAMA,2011,305(11) :1097-1105.
  • 5Steg PG,Harrington RA, Emanuelsson H, et al. Stentthrombosis with ticagrelor versus clopidogrel in patients withacute coronary syndromes; an analysis from the prospective,randomized PLATO trial[J]. Circulation,2013 , 128 (10) : 1055-1065.
  • 6Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis andmanagement of patients with stable ischemic heart disease: areport of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,and the American College of Physicians, American Associationfor Thoracic Surgery, Preventive Cardiovascular NursesAssociation, Society for Cardiovascular Angiography andInterventions,and Society of Thoracic Surgeons[J]. J Am CollCardiol,2012,60(24) :e44-el64.
  • 7Husted S, van Giezen JJ. Ticagrelor: the first reversibly bindingoral P2Y12 receptor antagonist[J]. Cardiovasc Ther, 2009T 27?4):259-274.
  • 8Htun WW, Steinhubl SR. Ticagrelor: the first novel reversibleP2Y?12) inhibitor[J]. Expert Opin Pharmacother,2013,14(2):237-245.
  • 9肖迎平.替格瑞洛改善急性冠脉综合征患者氯吡格雷抵抗的研究[D].河北医科大学2014
  • 10Hamm CW,Bassand JP,Agewall S,et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:the task force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2011,32:2999-3054.

共引文献304

同被引文献10

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部